SLAM
ANIP icon

Swiss Life Asset Management’s ANI Pharmaceuticals ANIP Stock Holding History

Swiss Life Asset Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$292K Buy
3,525
+121
+4% +$9.71K ﹤0.01% 1280
2026
Q1 		$262K Buy
3,404
+736
+28% +$57.4K ﹤0.01% 1204
2025
Q4 		$211K Buy
+2,668
New +$231K ﹤0.01% 1250

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Swiss Life Asset Management's ANIP Position: Q2 2026 in Review

Swiss Life Asset Management increased its ANI Pharmaceuticals (ANIP) stake by 3.6% in Q2 2026, buying an estimated $9.71K and bringing the position to 3,525 shares worth $292K. The position accounts for ﹤0.01% of the portfolio, ranked #1280.

Swiss Life Asset Management first reported a position in ANIP in Q4 2025 and has held it in 3 quarters since. 175 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Swiss Life Asset Management held 3,525 shares of ANI Pharmaceuticals worth $292K as of Q2 2026.
  • Swiss Life Asset Management bought 121 ANI Pharmaceuticals shares in Q2 2026, an estimated $9.71K.
  • ANI Pharmaceuticals made up ﹤0.01% of Swiss Life Asset Management's portfolio in Q2 2026, its #1280 holding.
  • Swiss Life Asset Management first reported a position in ANI Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 175 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.